The FDA rated the recall Class II and reports no illnesses. The North Carolina compounder got an FDA warning letter in December 2025. Lot numbers are listed at the source.
Recap by typeshit. Full story at FOX 32 Chicago.
8:58
Constable, who bills herself as a peptide expert, lists side effects she links to the unapproved triple agonist. Her claims, not trial data, so weigh them accordingly.
Lilly's retatrutide is still in development with no FDA approval, yet CBS investigators found vials labeled 'reta' easy to buy across the internet and in shops.
A $90 Brooklyn vial held a filler used in lip balm plus 13 bacteria colonies, University of Iowa testers said. Two online orders shipped with no consultation.
A systematic review cited by Dr. Axe found human safety data on BPC-157 comes from just 30 people, a thin base for a widely used peptide.
The Darling Ingredients unit says the supplement ingredient concentrates over ten neurosupportive peptides, with clinical trials planned to start in December.
The plastic surgeon weighs in on semaglutide and other GLP-1 drugs as more patients of every age turn to them for major weight loss.
Loading…